Details for Patent: 7,919,461
✉ Email this page to a colleague
Which drugs does patent 7,919,461 protect, and when does it expire?
Patent 7,919,461 protects OMONTYS and OMONTYS PRESERVATIVE FREE and is included in one NDA.
This patent has twenty-seven patent family members in eighteen countries.
Summary for Patent: 7,919,461
| Title: | Erythropoietin receptor peptide formulations and uses |
| Abstract: | The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided. |
| Inventor(s): | Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn Wynne (Campbell, CA), Naso; Robert Barnett (Menlo Park, CA) |
| Assignee: | Affymax, Inc. (Palo Alto, CA) |
| Application Number: | 11/777,500 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,919,461
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-007 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-008 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-001 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-003 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-004 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,919,461
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006255081 | ⤷ Sign Up | |||
| Brazil | PI0613233 | ⤷ Sign Up | |||
| Canada | 2609401 | ⤷ Sign Up | |||
| China | 101553242 | ⤷ Sign Up | |||
| Costa Rica | 9570 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 014528 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 200702656 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
